Aevi Genomic Medicine, Inc.: 10-Q filed 2013-11-07
What Aevi Genomic Medicine, Inc. reported in its quarterly report filed 2013-11-07 (fiscal Q3 2013): 21 published measures, 74 facts as tagged in accession 0001144204-13-059431.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2013-11-07
- Fiscal period
- fiscal Q3 2013
- Accession
- 0001144204-13-059431 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Aevi Genomic Medicine, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 28,320,000 | USD | |
| At 2012-12-31 | 7,707,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 6,372,000 | USD | |
| At 2012-12-31 | 5,773,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 21,948,000 | USD | |
| At 2012-12-31 | 1,934,000 | USD | |
| At 2012-09-30 | 3,214,000 | USD | |
| At 2011-12-31 | 2,997,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 26,791,000 | USD | |
| At 2012-12-31 | 6,431,000 | USD | |
| At 2012-09-30 | 8,999,000 | USD | |
| At 2011-12-31 | 4,995,000 | USD | |
| At 2000-01-26 | 0 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -6,143,000 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -11,921,000 | USD | 273 |
| 2000-01-27 to 2013-09-30 | -76,926,000 | USD | 4996 |
| 2012-07-01 to 2012-09-30 | -3,027,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -12,685,000 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -8,355,000 | USD | 273 |
| 2000-01-27 to 2013-09-30 | -52,810,000 | USD | 4996 |
| 2012-01-01 to 2012-09-30 | -5,874,000 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 159,000 | USD | 273 |
| 2000-01-27 to 2013-09-30 | 2,241,000 | USD | 4996 |
| 2012-01-01 to 2012-09-30 | 54,000 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 28,874,000 | USD | 273 |
| 2000-01-27 to 2013-09-30 | 81,669,000 | USD | 4996 |
| 2012-01-01 to 2012-09-30 | 9,932,000 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -159,000 | USD | 273 |
| 2000-01-27 to 2013-09-30 | -2,068,000 | USD | 4996 |
| 2012-01-01 to 2012-09-30 | -54,000 | USD | 274 |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 18,410,951 | shares | 92 |
| 2013-01-01 to 2013-09-30 | 17,435,235 | shares | 273 |
| 2012-07-01 to 2012-09-30 | 12,013,153 | shares | 92 |
| 2012-01-01 to 2012-09-30 | 10,604,924 | shares | 274 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 18,410,951 | shares | 92 |
| 2013-01-01 to 2013-09-30 | 17,468,255 | shares | 273 |
| 2012-07-01 to 2012-09-30 | 12,013,153 | shares | 92 |
| 2012-01-01 to 2012-09-30 | 10,604,924 | shares | 274 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 0 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 5,000 | USD | 273 |
| 2000-01-27 to 2013-09-30 | 100,000 | USD | 4996 |
| 2012-07-01 to 2012-09-30 | 1,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 9,000 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 381,000 | USD | |
| At 2012-12-31 | 352,000 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -4,904,000 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -11,924,000 | USD | 273 |
| 2000-01-27 to 2013-09-30 | -71,884,000 | USD | 4996 |
| 2012-07-01 to 2012-09-30 | -3,081,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -8,959,000 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 27,800,000 | USD | |
| At 2012-12-31 | 6,970,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 3,588,000 | USD | |
| At 2012-12-31 | 2,350,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 2,343,000 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 5,229,000 | USD | 273 |
| 2000-01-27 to 2013-09-30 | 34,498,000 | USD | 4996 |
| 2012-07-01 to 2012-09-30 | 1,611,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 3,356,000 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 18,481,308 | shares | |
| At 2012-12-31 | 12,307,808 | shares |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -6,143,000 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -11,916,000 | USD | 273 |
| 2000-01-27 to 2013-09-30 | -76,826,000 | USD | 4996 |
| 2012-07-01 to 2012-09-30 | -3,026,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -12,676,000 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 2,561,000 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 6,695,000 | USD | 273 |
| 2000-01-27 to 2013-09-30 | 40,290,000 | USD | 4996 |
| 2012-07-01 to 2012-09-30 | 1,470,000 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 5,603,000 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 130,000 | USD | 273 |
| 2000-01-27 to 2013-09-30 | 1,356,000 | USD | 4996 |
| 2012-01-01 to 2012-09-30 | 108,000 | USD | 274 |
Inspect the source
- Entity
- Aevi Genomic Medicine, Inc. / CIK 0001138776
- Captured
- SEC response SHA-256
16af7d8db7e8763eb25a11447dbdb1790b536242dd21d662c54ec3da77f91124
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001138776.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))